Related Experiment Video
Updated: May 23, 2026

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
Published on: June 4, 2021
Hemorrhagic complications of thrombolytic therapy
Zoran Vujković1, Dusko Racić, Sinisa Miljković
1Department of Neurology, Clinical Center Banjaluka, Bosnia and Herzegovina. vujkoviczoran@gmail.com
Abstract:
Stroke is the most frequent neurological disorder, and the most common cause of severe disability compared to other diseases. Recombinant tissue plasminogen activator (rt-PA) is the only approved specific therapy for acute ischemic stroke. Hemorrhage is a significant complication of thrombolytic treatment. This study, which included a hundred patients (52 male and 48 female), was aimed at assessing the safety according to our experience with 100 thrombolytic treatments for stroke. The death rate related to hemorrhage after thrombolysis was 3%. The frequency of hemorrhagic events (hemorrhagic infarctions type 1 and 2, parenchymal hematomas type 1 and 2) was 16%. The study results have shown that the intravenous recombinant tissue plasminogen activator (rt-PA) therapy is safe.
More Related Videos
Related Concept Videos
Hemorrhagic Stroke ll: Pathophysiology
Hemorrhagic Stroke l: Introduction
Venous Thrombosis III: Interprofessional Care
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis IV: Nursing Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

